{"id":"ad26-zebov-batch-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine uses a non-replicating adenoviral vector to deliver genetic instructions for producing the Ebola virus surface glycoprotein, triggering both cellular and humoral immune responses. The Ad26 vector is designed to be safe and immunogenic while avoiding integration into host DNA. It is typically administered as part of a heterologous prime-boost regimen with other Ebola vaccine candidates to enhance protective immunity.","oneSentence":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:30.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ebola virus disease prevention"}]},"trialDetails":[{"nctId":"NCT02543268","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09-21","conditions":"Healthy","enrollment":329}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ad26.ZEBOV-Batch #2","genericName":"Ad26.ZEBOV-Batch #2","companyName":"Crucell Holland BV","companyId":"crucell-holland-bv","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ad26.ZEBOV-Batch #2 is an intervention being studied in a clinical trial for its safety, tolerability, and immunogenicity in healthy adult participants. The exact mechanism of Ad26.ZEBOV-Batch #2 is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}